The characteristics and clinical outcome of drug-induced liver injury in a Chinese hospital

Chen, Sheng-Sen; Yu, Kangkang; Huang, Chong; Li, Ning; Zheng, Jianming; Bao, Suxia; Chen, Mingquan; Zhang, Wenhong

doi:10.1097/md.0000000000004683

Cited by 13 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were eight studies beyond the pseudo 95% confidence limits. Four of these that reported lower PPV were among studies with the largest sample sizes . The other four studies that reported higher PPV were studies with moderate sample sizes ranging from 130 to 688 .…”

Section: Resultsmentioning

confidence: 94%

“…Studies from Asia or Australia were published in more recent years. Majority of the studies included adult populations (62%), two studies (7%) included children aged 18 years and below, eight studies (28%) included a mixed adult and children population, while age limit was not reported in one study . Apart from two prospective studies with shorter study periods, the rest of the studies were conducted retrospectively.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review and meta‐analysis of algorithms used to identify drug‐induced liver injury (DILI) in health record databases

Tan

Low

Dan

et al. 2017

Liver International

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 94%

Section: Resultsmentioning

confidence: 99%

Systematic review and meta‐analysis of algorithms used to identify drug‐induced liver injury (DILI) in health record databases

Tan

Low

Dan

et al. 2017

Liver International

View full text Add to dashboard Cite

show abstract

“…The majority of patients with NAFLD (up to 70%) and ALD (up to 75%) experience significant functional impairment (including fatigue and cognitive difficulties) that affect activities of daily living and which persists over time . Fatigue is also a feature of drug‐induced liver injury (DILI), with approximately 40% of DILI experiencing clinically significant fatigue …”

Section: Fatigue In Liver Diseasementioning

confidence: 99%

“…19 Fatigue is also a feature of drug-induced liver injury (DILI), 26 with approximately 40% of DILI experiencing clinically significant fatigue. 27 These issues add significantly to the personal and societal burdens of these diseases and are an important driver of the indirect Terminology is also a significant issue with the word "fatigue" often meaning different things to different patients (and clinicians). Peripheral fatigue features can include a reduction in the degree or sustainability of suscle function.…”

Section: Incidence and Prevalencementioning

confidence: 99%

Fatigue in chronic liver disease: New insights and therapeutic approaches

Swain

Jones

2018

Liver International

View full text Add to dashboard Cite

The management of fatigue associated with chronic liver disease is a complex and major clinical challenge. Although fatigue can complicate many chronic diseases, it is particularly common in diseases with an inflammatory component. Fatigue can have both peripheral (i.e., neuromuscular) and central (i.e., resulting from changes in neurotransmission within the brain) causes. However, fatigue in chronic liver disease has strong social/contextual components and is often associated with behavioural alterations including depression and anxiety. Given the increasing awareness of patient-reported outcomes as important components of treatment outcomes and clinical research, there is a growing need to better understand and manage this poorly understood yet debilitating symptom. Although several pathophysiological mechanisms for explaining the development of fatigue have been generated, our understanding of fatigue in patients with chronic liver disease remains incomplete. A better understanding of the pathways and neurotransmitter systems involved may provide specific directed therapies. Currently, the management of fatigue in chronic liver disease can involve a combined use of methods to beneficially alter behavioural components and pharmacological interventions, of which several treatments have potential for the improved management of fatigue in chronic liver disease. However, evidence and consensus are lacking on the best approach and the most appropriate biochemical target(s) whilst clinical trials to address this issue have been few and limited by small sample size. In this review, we outline current understanding of the impact of fatigue and related symptoms in chronic liver disease, discuss theories of pathogenesis, and examine current and emerging approaches to its treatment.

show abstract

“…Она более изучена при холестатических заболеваниях, при других -ее распространенность определена хуже. По отдельным данным, ГУ/С обнаруживается у 70% пациентов с неалкогольной жировой болезнью печени (НАЖБП), у 75% -с алкогольной болезнью печени, у 40% -с лекарственными поражениями печени (ЛПП) [8,9]. Этот симптом ухудшает качество жизни и повседневную деятельность при заболеваниях печени [10,11], негативно влияет на физическую активность (73%), семейную жизнь (57%) и работу (30%) [12].…”

unclassified

Ademethionine in the treatment of fatigue in liver diseases: a systematic review

Райхельсон

Кондрашина

2019

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Fatigue has a significant effect on the condition of patients with liver disease. Ademethionine is considered one of the most promising drugs for its treatment. Aim. To systematize the published data on the treatment of hepatogenic fatigue with аdemethionine. Materials and methods. Search was performed using databases PubMed, EMBASE, Embase®, Medline®, eLIBRARY.ru, published in 1952-2018. Results and discussion. 16 articles were found on the use of ademethionine in liver diseases and the assessment of the dynamics of the symptom of fatigue, including 1 double-blind, randomized, placebo-controlled study, 3 open randomized studies; most of the works were multicenter open observation programs. The studies included 3238 patients (of which 2820 were included in the final data analysis) and a wide range of liver diseases: alcoholic liver disease, nonalcoholic fatty liver disease, primary biliary cholangitis, primary sclerosing cholangitis, cirrhosis of different causes, viral hepatitis, drug-induced liver injury. Different doses, routes of administration of аdemethionine and the duration of the course were used. Conclusions. Ademethionine, regardless of the route of administration, is effective in the treatment of fatigue due to different liver disease in the short and long term. The dose-dependent effect of the drug and the possibility of maintaining post-effect after end of the treatment course should be assumed, but this requires further study in randomized clinical trials.

show abstract

The characteristics and clinical outcome of drug-induced liver injury in a Chinese hospital

Abstract: Supplemental Digital Content is available in the text

Cited by 13 publications

References 34 publications

Systematic review and meta‐analysis of algorithms used to identify drug‐induced liver injury (DILI) in health record databases

Systematic review and meta‐analysis of algorithms used to identify drug‐induced liver injury (DILI) in health record databases

Fatigue in chronic liver disease: New insights and therapeutic approaches

Ademethionine in the treatment of fatigue in liver diseases: a systematic review

Contact Info

Product

Resources

About